Company Overview
Company Type: Public Company
Website: www.promisneurosciences.com
Number of Employees: 7
Ticker: PMN (NasdaqCM)
Year Founded: 2004


Business Description
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
48.5
EBITDA
(32.3)
Total Enterprise Value
46.7
TEV/EBITDA
NM
EBIT
(32.4)
Cash & ST Invst.
1.7
P/Diluted EPS Before Extra
NM
Net Income
(27.9)
Total Debt
0.0
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
2.0
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
-
-
(1.87)
(1.63)
(1.87)
Revenue (mm)
-
-
0.00
0.00
0.00
EBITDA (mm)
-
-
(21.00)
(16.50)
(21.00)

Forward Multiples (Current FY)

TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Buy (1.50)
Target Price
18.46
Potential Upside
577.50%


Key Professionals
Name
Title
Williams, Eugene 
Co-Founder & Chairman
Farfel, Gail M.
CEO & Director
Cashman, Neil R.
Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
Geffken, Daniel E.
Chief Financial Officer
Malenfant, Gavin T.
Chief Operating Officer
Altstiel, Larry Douglas
Chief Medical Officer
Bush, Ernest D.
Head of Pharmacology/Toxicology & Senior Consultant
Chen, Dennis 
Head of Manufacturing & Senior Consultant
Kaplan, Johanne 
Chief Development Officer
Wishart, David 
Chief Physics Officer

Key Board Members
Name
Title
Williams, Eugene 
Co-Founder & Chairman
Farfel, Gail M.
CEO & Director
Cashman, Neil R.
Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
Tanzi, Rudolph Emile
Chair of Scientific Advisory Board
Warma, Neil K. 
Independent Director
Shafmaster, Madge K.
Lead Independent Director
Burns, Nigel 
Member of Business Advisory Board
Cohen, Sharon 
Member of Scientific Advisory Board
Dagher, Alain 
Member of Scientific Advisory Board
Hastings, Michelle L.
Member of Scientific Advisory Board
Higgins, Michael J.
Member of Business Advisory Board
Kirwin, Patrick D.
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
1920 Yonge Street Suite 200 | Toronto, ON | M4S 3E2 | Canada
Phone: 416 847 6898   Fax: 416 847 6899

Current and Pending Investors
Affinity Asset Advisors, LLC, Ally Bridge Group, Altus Business Law Corporation, AuGC Partners LLC, Biogen Inc. (NasdaqGS:BIIB), BTIG, LLC, Crocker Mountain Capital, Darco Ventures II LLC, Dicot Holdings Ltd, Ernest W. Moody Revocable Trust, Genomics Ontario Inc., JAK II LLC, Jeremy M Sclar 2012 Irrevocable Family Trust, Kpc Investments, Llc, KPC Venture Capital LLC, Kraft Group LLC, Newco 224 Gmbh & Co. Kg, Norton Capital Limited, Ontario Genomics Institute, Quick Capital, LLC, RCap, LLC, Sphera Funds Management Ltd, Sphera Healthcare US Inc., T J Brown Living Trust, Title 19 Promis, Way Newington NH 03801, WFI Investments LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 2.73
Market Cap (mm)
50.5
Open
 2.67
Shares Out. (mm)
18.5
Previous Close
 2.73
Float %
70.5%
Change on Day
0.11
Shares Sold Short (mm)
0.1
Change % on Day
4.2%
Dividend Yield %
-
Day High/Low
 2.73/ 2.67
Diluted EPS Excl. Extra Items
(3.41)
52 wk High/Low
 12.20/ 2.05
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0034
Avg 3M Dly Vlm (mm)
0.35
Beta 5Y
0.68


 
Delayed Quote** | Last Updated on Oct-09-2023 12:00 AM (GMT-5)
NasdaqCM:PMN - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Exclusive Worldwide License To Novel Therapeutic Target For Alzheimer's Disease
As of November 12, 2015, Exclusive Worldwide License To Novel Therapeutic Target For Alzheimer's Disease was acquired by ProMIS Neurosciences Inc. Exclusive Worldwide License To Novel Therapeutic Target For Alzheimer's Disease comprises license to a novel Alzheimer's disease target.

United States and Canada
Biotechnology
-
-
-
Exclusive Worldwide License To Collective Coordinates
As of November 11, 2015, Exclusive Worldwide License To Collective Coordinates was acquired by ProMIS Neurosciences Inc. Exclusive Worldwide License To Collective Coordinates comprises a method to predict novel therapeutic targets in Alzheimer’s and other neurodegenerative diseases.

United States and Canada
Biotechnology
-
-
-
Luxor Developments Inc.
As of September 20, 2005, Luxor Developments Inc. was acquired by Amorfix Life Sciences Ltd. in a reverse merger transaction. Luxor Developments Inc. is a capital pool company. The company was founded in 1999 and is based in Edmonton, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-22-2023
-
Shelf Registration
Target
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)

Affinity Asset Advisors, LLC,Ally Bridge Group,Sphera Healthcare US Inc.,Sphera Funds Management Ltd,Title 19 Promis,Crocker Mountain Capital,Jeremy M Sclar 2012 Irrevocable Family Trust,KPC Venture Capital LLC,Darco Ventures II LLC,JAK II LLC,RCap, LLC,Dicot Holdings Ltd,Ernest W. Moody Revocable Trust,Newco 224 Gmbh & Co. Kg,T J Brown Living Trust,Norton Capital Limited,AuGC Partners LLC,WFI Investments LLC,Altus Business Law Corporation,BTIG, LLC Seller Funds:Sphera Biotech Master Fund L.P., Sphera Global Healthcare Master Fund, Affinity Healthcare Fund, LP, Deschutes Income Opportunity Fund LP, Ally Bridge MedAlpha Master Fund L.P.
46.47
Sep-22-2023
-
Shelf Registration
Target
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)


100.00
Aug-21-2023
Sep-08-2023
Private Placement
Target
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
Affinity Asset Advisors, LLC,Ally Bridge Group,Sphera Healthcare US Inc.

20.40
Nov-1-2022
Nov-14-2022
Shelf Registration
Target
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)

Kpc Investments, Llc,Quick Capital, LLC
13.84
Oct-11-2022
Oct-12-2022
Private Placement
Target
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
Kraft Group LLC

7.47
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-22-2023
Shelf Registration Filings
ProMIS Neurosciences, Inc. has filed a Shelf Registration in the amount of $46.469657 million.
Sep-22-2023
Shelf Registration Filings
ProMIS Neurosciences, Inc. has filed a Shelf Registration in the amount of $100 million.
Sep-12-2023
Company Conference Presentations
ProMIS Neurosciences, Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-12-2023 04:30 PM
Sep-08-2023
Private Placements
ProMIS Neurosciences, Inc. announced that it has received $20.4 million in funding from Affinity Asset Advisors, LLC, Ally Bridge Group, Sphera Healthcare US Inc.
Aug-21-2023
Private Placements
ProMIS Neurosciences, Inc. announced that it expects to receive funding from Affinity Asset Advisors, LLC, Ally Bridge Group, Sphera Healthcare US Inc. and others

Competitors
Eisai Co., Ltd. (TSE:4523), Eli Lilly and Company (NYSE:LLY), GE Healthcare Limited, GSK plc (LSE:GSK), nv Roche sa


Advisors
Most Recent Auditor
Baker Tilly Brasil Auditores Independentes S/S
Private Placement Advisors
BTIG, LLC, Cassels Brock & Blackwell LLP, Ceros Financial Services, Inc., Fraser Mackenzie Limited, Loewen Ondaatje McCutcheon Limited, Investment Banking Arm, Macquarie Private Wealth Inc., National Bank Financial, Inc., NOBLE Capital Markets, Inc., Northern Securities Inc., PI Financial Corp., Research Capital Corporation, Versant Partners Inc., Wolverton Securities Ltd
Public Offering Advisors
McMillan LLP, PricewaterhouseCoopers LLP, Canada


Most Recent Auditor
Baker Tilly


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
CFRA Equity Research

Oct 08, 2023 01:49 AM
PMN
ProMIS Neurosciences, Inc.
Reports
9
GlobalData

Oct 06, 2023 12:21 AM
PMN
ProMIS Neurosciences Inc (PMN.NASD) - Financial and Strategic SWOT Analysis Review
Reports
189
S&P Global Compustat

Oct 05, 2023 03:38 AM
PMN
ProMIS Neurosciences Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 05:17 AM
PMN
ValuEngine Rating and Forecast Report for PMN
Reports
11
GlobalData

Sep 20, 2023 01:17 AM
PMN
ProMIS Neurosciences Inc (PMN.NASD) - Financial and Strategic SWOT Analysis Review
Reports
189
GlobalData

Sep 15, 2023 10:45 AM
PMN
ProMIS Neurosciences Inc (PMN.NASD) - Medical Devices Product Pipeline Summary
Reports
69
GlobalData

Sep 15, 2023 06:24 AM
PMN
ProMIS Neurosciences Inc (ARFXF.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
73
GlobalData

Sep 15, 2023 02:01 AM
PMN
ProMIS Neurosciences Inc (PMN.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
94
GlobalData

Sep 12, 2023 06:30 AM
PMN
ProMIS Neurosciences Inc (ARFXF.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
64
S&P Global Compustat

Sep 07, 2023 03:24 AM
PMN
ProMIS Neurosciences Inc 2023_09_07
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Sphera Funds Management Ltd

1,834,042

9.90

4.8

Aug-23-2023


Gordon, Michael 

1,158,846

6.26

3.0

Aug-23-2023


Sclar, Jeremy M.

1,070,726

5.78

2.8

Aug-24-2023


Marks, Richard A.

769,763

4.16

2.0

Aug-24-2023


Williams, Eugene 

159,930

0.86

0.4

May-05-2023


Goldstein M.D., Elliot 

123,465

0.67

0.3

Oct-24-2022


Cashman M.D., Neil R.

114,921

0.62

0.3

Aug-23-2023


Northeast Financial Consultants, LLC

100,000

0.54

0.3

Jun-30-2023


Kirwin, Patrick D.

89,096

0.48

0.2

Aug-23-2023


Wyman, William W.

62,937

0.34

0.2

May-05-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Sphera Funds Management Ltd
1,834,042
1,834,042
Gordon, Michael 
1,158,846
797,872
Marks, Richard A.
769,763
664,894
Sclar, Jeremy M.
1,070,726
664,893
Farfel Ph.D., Gail M.
55,192
53,192

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Merrill Lynch & Co. Inc., Banking Investments
11,850
(1,199)
Morgan Stanley, Investment Banking and Brokerage Investments
1,808
(700)
JPMorgan Chase & Co, Brokerage and Securities Investments
4,896
(300)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Amyloid Vaccine (Future), Multivalent Peptide Vaccine (Future), PMN267 (Future), PMN300 (Future), PMN310 (Future), PMN320 (Future), PMN330 (Future), PMN340 (Future), PMN350 (Future), PMN442 (Future), ProMIS Target Identification Technology, ProMIS-BCNI antibody test (Future)


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-27-2023
-
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
SEC
S-3/A
442 KB
Sep-27-2023
-
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
SEC
S-3/A
130 KB
Sep-22-2023
-
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
SEC
S-3
528 KB
Sep-22-2023
-
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
SEC
POS AM
391 KB
Sep-22-2023
-
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
SEC
S-3
534 KB
Sep-18-2023
-
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
SEDAR
Material Change Report
777 KB
Sep-08-2023
-
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
SEDAR
News Releases
146 KB
Sep-06-2023
-
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
SEDAR
News Releases
167 KB
Aug-22-2023
-
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
SEC
424B3
588 KB
Aug-22-2023
Aug-21-2023
ProMIS Neurosciences, Inc. (NasdaqCM:PMN)
SEC
8-K (1.01, 3.02, 8.01, 9.01)
886 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Cashman M.D., Neil R. (Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director)
Aug-23-2023
Common Shares
10,643
-
Other Acquisition
10.21
Form 4
Farfel Ph.D., Gail M. (CEO & Director)
Aug-23-2023
Common Shares
53,192
-
Other Acquisition
2,659.60
Form 4
Kirwin, Patrick D. (Independent Director)
Aug-23-2023
Common Shares
11,000
-
Other Acquisition
14.09
Form 4
Malenfant, Gavin T. (Chief Operating Officer)
Aug-23-2023
Common Shares
2,660
-
Other Acquisition
New
Form 4
Milbury, Max A
Aug-23-2023
Common Shares
13,297
-
Other Acquisition
782.18
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Williams, Eugene 
Co-Founder & Chairman
(617) 460-0978
416 847 6899
eugene.williams@promisneurosciences.com
Farfel, Gail M.
CEO & Director
416 847 6898
416 847 6899

Cashman, Neil R.
Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
416 847 6898
416 847 6899

Tanzi, Rudolph Emile
Chair of Scientific Advisory Board
416 847 6898
416 847 6899

Warma, Neil K. 
Independent Director
416 847 6898
416 847 6899

Shafmaster, Madge K.
Lead Independent Director
416 847 6898
416 847 6899

Burns, Nigel 
Member of Business Advisory Board
416 847 6898
416 847 6899

Cohen, Sharon 
Member of Scientific Advisory Board
416 847 6898
416 847 6899

Dagher, Alain 
Member of Scientific Advisory Board
416 847 6898
416 847 6899

Hastings, Michelle L.
Member of Scientific Advisory Board
416 847 6898
416 847 6899

Higgins, Michael J.
Member of Business Advisory Board
416 847 6898
416 847 6899

Kirwin, Patrick D.
Independent Director
416 847 6898
416 847 6899

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Williams, Eugene 
Co-Founder & Chairman
(617) 460-0978
416 847 6899
eugene.williams@promisneurosciences.com
Farfel, Gail M.
CEO & Director
416 847 6898
416 847 6899

Cashman, Neil R.
Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
416 847 6898
416 847 6899

Geffken, Daniel E.
Chief Financial Officer
416 847 6898
416 847 6899

Malenfant, Gavin T.
Chief Operating Officer
416 847 6898
416 847 6899

Altstiel, Larry Douglas
Chief Medical Officer
416 847 6898
416 847 6899

Bush, Ernest D.
Head of Pharmacology/Toxicology & Senior Consultant
416 847 6898
416 847 6899

Chen, Dennis 
Head of Manufacturing & Senior Consultant
416 847 6898
416 847 6899

Kaplan, Johanne 
Chief Development Officer
416 847 6898
416 847 6899

Wishart, David 
Chief Physics Officer
416 847 6898
416 847 6899

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
